16th Annual Scientific Meeting
19 – 21 February, 2020 // Grand Hyatt, Washington DC
Distinguished Poster Award Recipient:
|
|||
Up-Front Matching for Prospective Observational Studies to Mimic Randomization (Turkoz) | |||
All Poster PDFs and Abstracts are available at the end of the second day. |
|||
19 February 2020 |
|||
Welcome from the President | Carla Canuso![]() ![]() |
||
Unresolved Problems in Neuroscience Drug Development | |||
Drugs with abuse liability: Issues facing their use as treatments for psychiatric disorders and how to address them
|
Chair: Walter Dunn![]() ![]() Discussants: Jerry Sanacora ![]() ![]() Charles Nemeroff ![]() ![]() Raye Litten ![]() ![]() |
||
Panel/Audience Discussion | ![]() |
||
Are current digital measures ready for prime time? | Chair: Phil Harvey Discussants: Elektra Papadopoulos ![]() ![]() Greg Strauss ![]() ![]() Valentina Mantua* |
||
Panel/Audience Discussion | ![]() |
||
Wednesday Working Group Sessions |
|||
Artificial Intelligence (AI) and Machine Learning (ML) for CNS Clinical Trials | Chairs: Adam Butler Larry Alphs summary |
||
Autism Spectrum Disorder | Chairs: Valentina Mantua Tiffany Farchione Celso Arango summary |
||
Behavioral and Psychiatric Symptoms in Dementia—Agitation Subgroup | Chairs: Cedric O’Gorman Paul Rosenberg summary |
||
Developing Integrated Interventions: Clinical Trials for Drug/Neuromodulation-Psychotherapy Combinations | Chairs: Walter Dunn Zimri Yaseen summary |
||
Estimands and Missing Data | Chairs: Pilar Lim Elena Polverejan summary |
||
Prevention Trials in Alzheimer’s Disease | Chairs: Holly Posner Phil Harvey |
||
20 February 2020 |
|||
Andrew C. Leon Distinguished Career Award Presentation | Steve Marder Carla Canuso ![]() Robert Heinssen ![]() |
||
Enhancing drug development through artificial intelligence (AI) and machine learning (ML) | Chairs: Adam Butler Larry Alphs Saeed Ahmed |
||
Introduction: Improving clinical trials with modern techniques | Adam Butler![]() ![]() |
||
What is artificial intelligence? | Saeed Ahmed![]() ![]() |
||
Applications of machine learning for psychiatry | Joe Geraci![]() ![]() |
||
Using AI/ML to differentiate drug and placebo responders in mood disorders: Offering the opportunity for enhanced patient selection | Jane Tiller ![]() ![]() |
||
AI-enabled digital phenotyping as a vehicle for clinical trial qualification and tracking of change during intervention | Dennis Wall* |
||
Regulatory considerations when utilizing AI and ML applications in the design and execution of a CNS clinical trial | David Millis![]() ![]() |
||
Panel Discussion | Discussant: Vikas Mohan Sharma ![]() ![]() |
||
Summary | |||
The Brain – Gut Axis in Psychiatry and Neurology: Focus on the Microbiome | Chairs: Jill Rasmussen Ron Marcus |
||
Introduction | Jill Rasmussen![]() ![]() |
||
Microbes, brain and behavior- Focus on depression | Ted Dinan![]() ![]() |
||
The brain immune gut axis- a big approach to developing new medications for psychiatric disorders in the new decade | Robert Yolken![]() ![]() |
||
Microbiome and Alzheimer’s disease | Miia Kivipelto![]() ![]() |
||
Microbiome and Parkinson disease: Therapeutic implications | Peter LeWitt![]() ![]() |
||
Regulatory considerations for microbiome based therapeutics | Paul Carlson![]() ![]() Luca Pani ![]() |
||
Panel / Audience Discussion | Facilitator: Ron Marcus ![]() |
||
Is There a Fundamental Rethinking in the Way We Plan Clinical Trials? The Estimand Change in Mindset | Chairs: Pilar Lim Michael Davis Steve Brannan |
||
Introduction | Pilar Lim![]() ![]() |
||
Introduction to the ICH E9(R1) Addendum on “Estimands and Sensitivity Analysis in Clinical Trials”: A clinical perspective | Florence Butlen-Ducuing![]() ![]() |
||
Putting the ICH E9(R1) Guidance into practice – A multi-disciplinary collaboration | Elena Polverejan![]() ![]() |
||
Development of an estimand for acute treatment of Major Depressive Disorder trials: Keeping the new mindset in mind | Zimri Yaseen![]() ![]() |
||
Regulatory implications of the ICH E9(R1) Guidance | Robert Temple![]() ![]() |
||
Panel and Regulatory Discussion | Facilitator: Michael Davis Panelists: James Hung Michael O’Kelly Marc Walton ![]() |
||
Summary | Michael Davis |
||
Poster Session/Reception | Poster PDFs and Abstracts | ||
21 February 2020
|
|||
Friday Working Group Sessions |
|||
Assessment Methods and Endpoints for Rapid-Acting Antidepressants-RAADs | Chairs: Mark Opler Elizabeth Ballard Christian Yavorsky summary |
||
Behavioral and Psychiatric Symptoms in Dementia—Apathy Subgroup | Chairs: Krista Lanctôt David Miller summary |
||
Curriculum Development – Advanced CNS Clinical Trials Course | Chairs: Carla Canuso Kari Nations summary |
||
Innovative Technologies for Clinical Trials | Chairs: Richard Keefe Michael Davis summary |
||
Orphan Diseases | Chairs: Joan Busner Gahan Pandina Ravi Anand summary |
||
Role of Reward Processing Assessment as a Tool in Drug Development | Chairs: Larry Ereshefsky Raimund Buller |
||
Introduction | Raimund Buller Larry Ereshefsky ![]() |
||
The neurobiology of anhedonia: Circuitry and relevance to drug development and patient stratification | Diego Pizzagalli![]() ![]() |
||
Reward processing mechanisms underlying negative symptoms in schizophrenia | Gregory Strauss![]() ![]() |
||
Reward processing in neurological disorders: Focus on Parkinson’s disease | Masud Husain![]() ![]() |
||
Pragmatic aspects of including reward processing tasks in drug development trials | Stephane Pollentier![]() ![]() |
||
Comment: Translational considerations – NIMH | Sarah Lisanby![]() ![]() |
||
Regulatory view on use of reward processing in patient segmentation and as a marker for treatment response | Tiffany Farchione![]() ![]() |
||
Panel / Audience Discussion | ![]() |
||
Summary | |||
Meeting Adjourned
*Slides not released |
Ramy Mahmoud![]() |